Antileukemic impact of glucocorticoid use in acute lymphoblastic leukaemia treatment
Meri A. Shervashidze,
Daria S. Smirnova,
Timur T. Valiev,
Kirill I. Kirgizov,
Svetlana R. Varfolomeeva https://doi.org/10.15690/pf.v20i4.2603
Abstract
Glucocorticoids (GC) are used as anti-inflammatory, immunosupressive and anti-tumor agents for several decades due to their ability to cell cycle inhibition and apoptosis induction but mechanism of action is not fully explored. Glucocorticoids play one of the key roles in acute lymphoblastic leukaemia treatment and are at the forefront in induction and reinduction phases. The response of tumor clone to GC determines a risk group and prognosis. A number of mechanisms of antileukemic action and resistance factors will be describe in this article.
Supporting agencies: Not specified.
About the Authors
Meri A. Shervashidze
N.N. Blokhin National Medical Research Centre of Oncology
Russian Federation
Disclosure of interest:
Russian Federation
MD.
Moscow
Disclosure of interest:
None
Daria S. Smirnova
N.N. Blokhin National Medical Research Centre of Oncology
Russian Federation
Disclosure of interest:
Russian Federation
MD.
Moscow
Disclosure of interest:
None
Timur T. Valiev
N.N. Blokhin National Medical Research Centre of Oncology
Russian Federation
Disclosure of interest:
Russian Federation
MD, PhD.
24 Kashirskoe shosse, Moscow, 115478
tel.: +7 (905) 797-70-06
Disclosure of interest:
None
Kirill I. Kirgizov
N.N. Blokhin National Medical Research Centre of Oncology
Russian Federation
Disclosure of interest:
Russian Federation
MD, PhD.
Moscow
Disclosure of interest:
None
Svetlana R. Varfolomeeva
N.N. Blokhin National Medical Research Centre of Oncology
Russian Federation
Disclosure of interest:
Russian Federation
MD, PhD, Professor.
Moscow
Disclosure of interest:
None
References
1. Hunger SP. Glucocorticoid selection for pediatric ALL. Blood. 2016;127(17):2049-2051. doi: https://doi.org/10.1182/blood-2016-02-701664
2. Jing D, Bhadri VA, Beck D, et al. Opposing regulation of BIM and BCL2 controls glucocorticoid-induced apoptosis of pediatric acute lymphoblastic leukemia cells. Blood. 2015;125(2):273-283. doi: https://doi.org/10.1182/blood-2014-05-576470
3. Inaba H, Pui CH. Glucocorticoid use in acute lymphoblastic leukaemia. Lancet Oncol. 2010;11(11):1096-1106. doi: https://doi.org/10.1016/S1470-2045(10)70114-5
4. Gruber G, Carlet M, Turtscher E, et al. Levels of glucocorticoid receptor and its ligand determine sensitivity and kinetics of glucocorticoid-induced leukemia apoptosis. Leukemia. 2009;23(4):820-823. doi: https://doi.org/10.1038/leu.2008.360
5. Gross KL, Lu NZ, Cidlowski JA. Molecular mechanisms regulating glucocorticoid sensitivity and resistance. Mol Cell Endocrinol. 2009;300(1-2):7-16. doi: https://doi.org/10.1016/j.mce.2008.10.001
6. Carlet M, Janjetovic K, Rainer J, et al. Expression, regulation and function of phosphofructo-kinase/fructose-biphosphatases (PFKFBs) in glucocorticoid-induced apoptosis of acute lymphoblastic leukemia cells. BMC Cancer. 2010;10:638. doi: https://doi.org/10.1186/1471-2407-10-638
7. Vandewalle J, Luypaert A, De Bosscher K, Libert C. Therapeutic Mechanisms of Glucocorticoids. Trends Endocrinol Metab. 2018;29(1):42-54. doi: https://doi.org/10.1016/j.tem.2017.10.010
8. Catts VS, Farnsworth ML, Haber M, et al. High level resistance to glucocorticoids, associated with a dysfunctional glucocorticoid receptor, in childhood acute lymphoblastic leukemia cells selected for methotrexate resistance. Leukemia. 2001;15(6):929-935. doi: https://doi.org/10.1038/sj.leu.2402128
9. Sun F, Zhou JL, Wei SX, et al. Glucocorticoids induce osteonecrosis of the femoral head in rats via PI3K/AKT/FOXO1 signaling pathway. PeerJ. 2022;10:e13319. doi: https://doi.org/10.7717/peerj.13319
10. Schmidt S, Rainer J, Ploner C, et al. Glucocorticoid-induced apoptosis and glucocorticoid resistance: molecular mechanisms and clinical relevance. Cell Death Differ. 2004;11(Suppl 1):S45-S55. doi: https://doi.org/10.1038/sj.cdd.4401456
11. Ausserlechner MJ, Obexer P, Bock G, et al. Cyclin D3 and c-MYC control glucocorticoid-induced cell cycle arrest but not apoptosis in lymphoblastic leukemia cells. Cell Death Differ. 2004;11(2):165-174. doi: https://doi.org/10.1038/sj.cdd.44013281
12. Mansha M, Carlet M, Ploner C, et al. Functional analyses of Src-like adaptor (SLA), a glucocorticoid-regulated gene in acute lymphoblastic leukemia. Leuk Res. 2010;34(4):529-534. doi: https://doi.org/10.1016/j.leukres.2009.06.029
13. Gardner JP, Zhang L. Glucocorticoid modulation of Ca2+ homeostasis in human B lymphoblasts. J Physiol. 1999;514(Pt 2):385-396. doi: https://doi.org/10.1111/j.1469-7793.1999.385ae.x
14. Durmaz B, Bagca BG, Cogulu O, et al. Antileukemic Effects of Anti-miR-146a, Anti-miR-155, Anti-miR-181a, and Prednisolone on Childhood Acute Lymphoblastic Leukemia. Biomed Res Int. 2021;2021:3207328. doi: https://doi.org/10.1155/2021/3207328
15. Distelhorst CW. Recent insights into the mechanism of glucocorticosteroid-induced apoptosis. Cell Death Differ. 2002;9(1):6-19. doi: https://doi.org/10.1038/sj.cdd.4400969
16. Schmidt S, Rainer J, Riml S, et al. Identification of glucocorticoidresponse genes in children with acute lymphoblastic leukemia. Blood. 2006;107(5):2061-2069. doi: https://doi.org/10.1182/blood-2005-07-2853
17. Orkin SH, Fisher DE, Ginsburg D, et al. Nathan and Oskis Hematology and Oncology of Infancy and Childhood. 8th edition. Elsevier Saunders, 2015, 2752p
Review
For citations:
Shervashidze M.A., Smirnova D.S., Valiev T.T., Kirgizov K.I., Varfolomeeva S.R. Antileukemic impact of glucocorticoid use in acute lymphoblastic leukaemia treatment. Pediatric pharmacology. 2023;20(4):303-308. (In Russ.) https://doi.org/10.15690/pf.v20i4.2603
Views:
647
Email this article 